STAT+: Why a Huntington's patient isn't fazed by the waning effect of UniQure's gene therapy

STAT reports that questions about the durability of UniQure's experimental Huntington's disease gene therapy matter to Wall Street, but matter less to those directly affected by the disease; one patient is not fazed by its waning effect. The therapy remains experimental, and the report draws no efficacy conclusion.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.